The Jab1 level was found to be a possible biomarker for clinical response to chemotherapy in lung cancer patients and for postoperative relapse in breast cancer patients who received adjuvant chemotherapy (Hou et al., 2017), indicating that Jab1 predicts treatment response in lung cancer and relapse in breast cancer patients. The gene discussed is COPS5; the disease is lung cancer.